Immix Biopharma announced the addition of three additional clinical trial sites for its U.S. relapsed/refractory AL amyloidosis clinical trial NEXICART-2. “The newly added centers include some of the leading programs in the world in AL Amyloidosis. New sites expand opportunities for patient access to CAR-T NXC-201 across the U.S. MSKCC remains the lead clinical site,” the company said in a statement.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMX:
- Immix Biopharma awarded $8M CLIN2 grant
- California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
- Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
- Immix Biopharma doses first patient in U.S. AL amyloidosis trial with NXC-201
- Immix Biopharma initiated with a Buy at H.C. Wainwright
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue